NAFLD 2020 - updates in diagnosis and management

Philip N. Newsome

doi:10.2957/kanzo.61.A7

NAFLD 2020 - updates in diagnosis and management

Philip N. Newsome^*

^*Corresponding author for this work

Medicine and Health

Research output: Contribution to journal › Article › peer-review

Abstract

Non-alcoholic fatty liver disease is caused by the increased deposition of fat in the liver as occurs in the setting of adiposity and/or diabetes. It is increasingly common, and now accounts for a larger proportion of patients being considered for liver transplantation. My talk will focus firstly on the tools that can be used to identify those patients that are at the greatest risk of having more advanced liver fibrosis. Then I will cover the strategies to help in the management of such patients which includes behavioural change as well as the many emerging pharmacotherapies.

Original language	English
Pages (from-to)	A8-A9
Journal	Kanzo/Acta Hepatologica Japonica
Volume	61
DOIs	https://doi.org/10.2957/kanzo.61.A7
Publication status	Published - 2020

Bibliographical note

Publisher Copyright:
© 2020, Japan Society of Hepatology. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hepatology

Access to Document

10.2957/kanzo.61.A7

Cite this

@article{86e932bad75c42b9858a43d3cf8e7a45,

title = "NAFLD 2020 - updates in diagnosis and management",

abstract = "Non-alcoholic fatty liver disease is caused by the increased deposition of fat in the liver as occurs in the setting of adiposity and/or diabetes. It is increasingly common, and now accounts for a larger proportion of patients being considered for liver transplantation. My talk will focus firstly on the tools that can be used to identify those patients that are at the greatest risk of having more advanced liver fibrosis. Then I will cover the strategies to help in the management of such patients which includes behavioural change as well as the many emerging pharmacotherapies.",

author = "Newsome, \{Philip N.\}",

year = "2020",

doi = "10.2957/kanzo.61.A7",

language = "English",

volume = "61",

pages = "A8--A9",

journal = "Kanzo/Acta Hepatologica Japonica",

issn = "0451-4203",

}

TY - JOUR

T1 - NAFLD 2020 - updates in diagnosis and management

AU - Newsome, Philip N.

PY - 2020

Y1 - 2020

N2 - Non-alcoholic fatty liver disease is caused by the increased deposition of fat in the liver as occurs in the setting of adiposity and/or diabetes. It is increasingly common, and now accounts for a larger proportion of patients being considered for liver transplantation. My talk will focus firstly on the tools that can be used to identify those patients that are at the greatest risk of having more advanced liver fibrosis. Then I will cover the strategies to help in the management of such patients which includes behavioural change as well as the many emerging pharmacotherapies.

AB - Non-alcoholic fatty liver disease is caused by the increased deposition of fat in the liver as occurs in the setting of adiposity and/or diabetes. It is increasingly common, and now accounts for a larger proportion of patients being considered for liver transplantation. My talk will focus firstly on the tools that can be used to identify those patients that are at the greatest risk of having more advanced liver fibrosis. Then I will cover the strategies to help in the management of such patients which includes behavioural change as well as the many emerging pharmacotherapies.

UR - https://www.scopus.com/pages/publications/85099185567

U2 - 10.2957/kanzo.61.A7

DO - 10.2957/kanzo.61.A7

M3 - Article

AN - SCOPUS:85099185567

SN - 0451-4203

VL - 61

SP - A8-A9

JO - Kanzo/Acta Hepatologica Japonica

JF - Kanzo/Acta Hepatologica Japonica

ER -

NAFLD 2020 - updates in diagnosis and management

Abstract

Bibliographical note

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this